SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance

SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance

• Q3 2025 revenues up 3% yoy at constant currencies to EUR 256m
• Q3 2025 EBITDA up 11% yoy to EUR 83m, with a quarterly margin of 32.4% (31.7% at constant currencies)
• Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management expectations between 6.0% and 9.0% (“high-single digit”)
• The EBITDA margin for FY 2025 is expected to be around 28.0%, above the previous guidance of “approximately at the level of FY 2024 (26.9%)”
• The full set of Q3/9M 2025 financial results will be published on August 12, 2025

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, continued its trajectory of profitable growth in the third quarter of the fiscal year 2025¹. In Q3 2025, revenues increased by 1% to EUR 256m (Q3 2024: EUR 254m), which corresponds to a 3% year-over-year (yoy) growth at constant currencies. The growth was primarily driven by a strong demand for the strong-margin High Value Solutions (HVS), which accounted for 60% of revenues, a yoy increase of 5 percentage points. Benefitting from a positive product mix shift towards HVS and efficiency gains, EBITDA grew to EUR 83m (Q3 2024: EUR 74m), an increase of 11% both reported and at constant currencies. This resulted in a quarterly margin of 32.4% (Q3 2024: 29.4%) or 31.7% at constant currencies. Based on the preliminary results in the first nine months and the outlook for the full fiscal year 2025, SCHOTT Pharma is specifying its full year guidance.

For the fiscal year 2025, the company now expects organic revenue growth of around 6.0% at constant currencies, specified from “high-single digits”. This specification to the lower end of the management’s prior expectation of between 6.0% and 9.0% reflects the most recent market dynamics following increased uncertainty given ongoing global policy discussions which impact industry sentiment.

Regarding profitability, the company increases its EBITDA margin guidance to around 28.0%, above the previous guidance of “approximately at the level of FY 2024 (26.9%)”. The continued high demand for strong-margin HVS, particularly sterile cartridges and specialty vials, led to a beneficial product mix. In addition, SCHOTT Pharma’s ongoing measures to improve operational performance and efficiency are positively impacting the company’s EBITDA.

SCHOTT Pharma will publish its full set of financials for Q3/9M 2025 on August 12, 2025. Andreas Reisse (CEO) and Reinhard Mayer (CFO) will report the Q3 2025 results in an analyst and investor conference call at 11:00 a.m. CEST.

For additional news about SCHOTT Pharma please visit our media center.

Key figures Q3 2025 

Key figures 9M 2025 

 ¹The fiscal year runs from October to September. Q3 2025 therefore relates to the period from April 2025 to June 2025.

²cc = at constant currencies

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com  

Contact

Lea Kaiser 

PR & Communications Manager 

Tel.: +49 (0) 151 68917195 

E-Mail: lea.kaiser@schott.com 

Tobias Erfurth 

Head of Investor Relations 

E-Mail: ir.pharma@schott.com 

Jasko Terzic, CFA 

Senior Manager Investor Relations 

E-Mail: ir.pharma@schott.com